Patents by Inventor Donna Neuberg

Donna Neuberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for determining response to a hypomethylating agent
    Patent number: 11015223
    Abstract: Disclosed are methods for predicting a response of a subject with myelodysplastic syndrome to treatment with a hypomethylating agent, for example using a sample obtained from the subject. The methods can be used to select a subject for treatment with a hypomethylating agent, and/or measure a subject's response to therapy and/or disease progression/regression. The methods include detecting, in a nucleic acid sample obtained from a subject, one or more mutations of any one or more genes selected from Table 3a.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: May 25, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAT . INC
    Inventors: Rafael Bejar, Benjamin Ebert, Donna Neuberg, Kristen Stevenson
  • Mutation signatures for predicting the survivability of myelodysplastic syndrome subjects
    Patent number: 10711308
    Abstract: Somatic non-silent mutations on selected biomarkers are reliable indicators for the overall survival of Myelodysplastic Syndrome subjects.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: July 14, 2020
    Assignees: BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Rafael Bejar, Benjamin Levine Ebert, Kristen Stevenson, Donna Neuberg
  • METHODS FOR DETERMINING RESPONSE TO A HYPOMETHYLATING AGENT
    Publication number: 20160083802
    Abstract: Disclosed are methods for predicting a response of a subject with myelodysplastic syndrome to treatment with a hypomethylating agent, for example using a sample obtained from the subject. The methods can be used to select a subject for treatment with a hypomethylating agent, and/or measure a subject's response to therapy and/or disease progression/regression. The methods include detecting, in a nucleic acid sample obtained from a subject, one or more mutations of any one or more genes selected from Table 3a.
    Type: Application
    Filed: May 12, 2014
    Publication date: March 24, 2016
    Inventors: Rafael BEJAR, Benjamin EBERT, Donna NEUBERG, Kristen STEVENSON
  • Mutation Signatures for Predicting the Survivability of Myelodysplastic Syndrome Subjects
    Publication number: 20140127690
    Abstract: Somatic non-silent mutations on selected biomarkers are reliable indicators for the overall survival of Myelodysplastic Syndrome subjects.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 8, 2014
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Rafael Bejar, Benjamin Levine Ebert, Kristen Stevenson, Donna Neuberg